Host Serine Proteases: A Potential Targeted Therapy for COVID-19 and Influenza

Abstract

The ongoing pandemic illustrates limited therapeutic options for controlling SARS-CoV-2 infections, calling a need for additional therapeutic targets. The viral spike S glycoprotein binds to the human receptor angiotensin-converting enzyme 2 (ACE2) and then is activated by the host proteases. Based on the accessibility of the cellular proteases needed for SARS-S activation, SARS-CoV-2 entrance and activation can be mediated by endosomal (such as cathepsin L) and non-endosomal pathways. Evidence indicates that in the non-endosomal pathway, the viral S protein is cleaved by the furin enzyme in infected host cells. To help the virus enter efficiently, the S protein is further activated by the serine protease 2 (TMPRSS2), provided that the S has been cleaved by furin previously. In this review, important roles for host proteases within host cells will be outlined in SARS-CoV-2 infection and antiviral therapeutic strategies will be highlighted. Although there are at least five highly effective vaccines at this time, the appearance of the new viral mutations demands the development of therapeutic agents. Targeted inhibition of host proteases can be used as a therapeutic approach for viral infection.

A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants

“…Nelfinavir, a leading HIV protease inhibitor, has been shown to target the SARS-CoV-2 main protease to inhibit virus replication [ 19 ]. Camostat mesylate, naphthofluorescein, E64d, and decanoyl-RVKR-CMK have been widely used to study the virus entry and spike processing by targeting host cell proteases [ 20 ]. Fluvoxamine is a selective serotonin reuptake inhibitor that is approved by the FDA to treat obsessive–compulsive disorder.…”

The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication

“…After binding to the receptor, proteolytic cleavage of SARS-CoV-2 S protein enables the S2 subunit-assisted fusion of viral and cellular membranes. This process is mediated via certain host proteases including furin, cell surface transmembrane serine proteases 2 (TMPRSS2), 31 cathepsins B and L, factor Xa and elastase. An insertion of four amino acids in the S1/S2 site of S protein provides a minimal cleavage motif (RRAR) recognized by proprotein convertase furin, which is a unique feature of SARS-CoV-2.…”

DPP-4 Inhibitors as a Savior for COVID-19 Patients with Diabetes

“…As a result, the S2' site of the viral spike protein is activated and forms a 6-helix bundle fusion core (6-HB) of heptad repeat 1 (HR1) and 2 (HR2) from S2 subunit. This promotes fusion of the host cell and viral membrane, and subsequent endocytosis of the virus ( Figure 1 ) [ 31–34 ].…”